New study targets colorectal cancer in underrepresented minorities

NCT ID NCT06562543

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This phase 4 trial is testing the safety and effectiveness of the oral drug fruquintinib in 78 adults from minority groups (Black/African American and Hispanic/Latino) with advanced colorectal cancer that hasn't responded to other treatments. The main focus is on how often high blood pressure occurs as a side effect. Participants take fruquintinib in 4-week cycles until their disease worsens or side effects become too much.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: fruquintinib (Fruzaqla™)
What this could lead to: If successful, this could show that fruquintinib is safe and effective for minority patients with advanced colorectal cancer, helping to address gaps in treatment knowledge.
What could go wrong: This is a small, single-arm study with no comparison group, so results may not be definitive. Hypertension is a known side effect, and the trial may not lead to new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 78 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provide written (or electronic) informed consent. 2. Male or female aged more than or equal to (≥)18 years. 3. Presence of histologically and/or cytologically documented metastatic colorectal adenocarcinoma. Rat sarcoma virus (RAS) status for each participant must be documented. 4. Have been previously treated with standard approved therapies: * Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, * An anti-vascular endothelial growth factor (VEGF) biological therapy (e.g., bevacizumab, aflibercept, ramucirumab \[regorafenib is NOT an anti-VEGF biologic\]), and * If RAS wild-type and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy (e.g., cetuximab, panitumumab). * If known microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumor and medically appropriate, a programmed cell death protein 1 (PD1) inhibitor. 5. Self-identify as Black and/or African American or Hispanic and/or Latino or as both. 6. Body weight ≥40 kilograms (kg). 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening. 8. Have assessable disease according to RECIST version 1.1, assessed locally. 9. In participants of childbearing potential, agreement to use highly effective form(s) of contraception, which results in a low failure rate (less than \[\<\]1 percent \[%\] per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire trial period, and for 2 weeks after taking the last dose of the trial intervention. Such methods include oral (PO) hormonal contraception (combined estrogen/progestogen or progestogen-only) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system (IUS), bilateral tubal ligation, vasectomized partner, or true sexual abstinence in line with the preferred and usual lifestyle of the participant. Those assigned male sex at birth must always use a condom. Exclusion Criteria: 1. Absolute neutrophil count (ANC) \<1.5 times 10\^9 per liter (10\^9/L), platelet count \<100 times 10\^9/L, or hemoglobin \<9.0 grams per deciliter (g/dL). Blood transfusion within 1 week prior to enrollment for the purpose of increasing the likelihood of eligibility is not allowed. 2. Serum total bilirubin more than (\>)1.5 times the upper limit of normal range (ULN). Participants with previously documented Gilbert syndrome and bilirubin \<2 times ULN are eligible. 3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 times ULN in participants without hepatic metastases; ALT or AST \>5 times ULN in participants with hepatic metastases. 4. Creatinine clearance \<30 milliliters per minute (mL/min). Creatinine clearance can either be measured in a 24-hour urine collection or estimated by the Cockcroft-Gault equation. Where available and appropriate, other formulae may be used to estimate clearance after consultation with the trial medical monitor. 5. Urine dipstick or urinalysis with protein ≥2 positive or 24-hour urine protein ≥1.0 gram per 24 hours (g/24 hours). Participants with 1+ positive proteinuria must undergo a 24-hour urine collection to assess urine protein level. 6. Uncontrolled hypertension, defined as systolic BP ≥140 millimeter of mercury (mmHg) and/or diastolic blood pressure (BP) ≥90 mmHg despite optimal medical management. The participant must have BP below both limits. Repeated assessments are permitted. 7. International normalized ratio (INR) \>1.5 times ULN or activated partial thromboplastin time (aPTT) \>1.5 times ULN, unless the participant is currently receiving or intended to receive anticoagulants for prophylactic purposes. 8. History of or active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history of perforation or fistulas, or any other condition that could, in the investigator's judgment, result in gastrointestinal hemorrhage or perforation within the 6 months prior to screening. 9. History or presence of hemorrhage from any other site (e.g, hemoptysis or hematemesis) within 2 months prior to screening. 10. History of a thromboembolic event, including deep vein thrombosis, pulmonary embolism, or arterial embolism within 6 months prior to screening. 11. Stroke and/or transient ischemic attack within 12 months prior to screening. 12. Clinically significant cardiovascular disease, including but not limited to, acute myocardial infarction or coronary artery bypass surgery within 6 months prior to enrollment, severe or unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left ventricular ejection fraction \<50% by echocardiogram. 13. QT interval, corrected using the Fridericia method (QTcF) \>480 milliseconds or any factors that increase the risk of QT interval, corrected based on the patient's heart rate (QTc) prolongation or risk of arrhythmic events such as hypokalemia, congenital long QT syndrome, or family history of long QT syndrome. 14. Systemic antineoplastic therapies (except for that described in exclusion criterion no. 15) or any investigational therapy within 2 weeks prior to the first dose of the trial intervention, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy, and immunotherapy. 15. Systemic small molecule targeted therapies (e.g., tyrosine kinase inhibitors \[TKIs\]) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of the trial intervention. 16. Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of the trial intervention. 17. Brachytherapy (i.e., implantation of radioactive seeds) within 60 days prior to the first dose of the trial intervention. 18. Surgery or invasive procedure (i.e., a procedure that includes a biopsy; central venous catheter placement is allowed) within 14 days prior to the first dose of the trial intervention or unhealed surgical incision. 19. Any unresolved toxicities from previous antitumor treatments greater than NCI CTCAE, version 5.0, Grade 1 (except for alopecia or neurotoxicity Grade less than or equal to \[≤\]2). 20. Known human immunodeficiency virus infection. 21. Known history of active viral hepatitis. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load had to be undetectable on suppressive therapy, if indicated. Participants with hepatitis C virus (HCV) infection who are currently on treatment are eligible if they have an undetectable HCV viral load. 22. Clinically uncontrolled active infection requiring intravenous (IV) antibiotics. 23. Tumor invasion of a large vascular structure (e.g., pulmonary artery or superior or inferior vena cava). 24. Those who are currently pregnant or lactating. 25. Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of SD for 14 days or longer; participants requiring steroids within 4 weeks prior to the start of the trial intervention are to be excluded. 26. Other malignancy, except for non-melanoma skin cancer, in situ cervical carcinoma, or bladder carcinoma (tumor in situ and T1) that had been adequately treated during the 5 years prior to screening. Participants with another primary malignancy that has been adequately treated may be included after consultation with the trial medical monitor. 27. Inability to take medication PO, dysphagia, or an active gastric ulcer resulting from previous surgery (e.g., gastric bypass) or a severe gastrointestinal disease, or any other condition that investigators believe might affect absorption of the investigational medicinal product (IMP). 28. Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition (e.g., current alcohol or drug abuse) that investigators suspect might prohibit use of the IMP, affect interpretation of trial results, or put the participant at undue risk of harm based on the investigator's assessment. 29. Known hypersensitivity to fruquintinib or any of its inactive ingredients, including the azo dyes Tartrazine- Federal Food, Drug, and Cosmetic Act (FD\&C) Yellow 5 and Sunset yellow For Coloring Food (FCF)-FD\&C Yellow 6. 30. Received prior fruquintinib. 31. Live vaccine ≤28 days before the first dose of the trial intervention. Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed. 32. Use of strong inducers of cytochrome P450 3A4 (CYP3A4) within 2 weeks before the first dose of the trial intervention.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

The study's own enquiry address

This study publishes an address for enquiries. See it below .
The places running it

32 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Albert Einstein College of Medicine
WITHDRAWN

The Bronx, New York, 10461, United States
BRCR Global
WITHDRAWN

Katy, Texas, 77450, United States
Baptist Health - Miami Cancer Institute
WITHDRAWN

Miami, Florida, 33176, United States
Baylor College of Medicine
RECRUITING

Houston, Texas, 77054, United States
Boston Medical Center
WITHDRAWN

Boston, Massachusetts, 02118, United States
Capital Health Medical Center - Hopewell
RECRUITING

Pennington, New Jersey, 08534, United States
Central Alabama Research
RECRUITING

Birmingham, Alabama, 35209, United States
Christiana Care Health Services
RECRUITING

Newark, Delaware, 19713, United States
Columbia University
WITHDRAWN

New York, New York, 10032, United States
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Fox Chase Cancer Center | Philadelphia, PA
WITHDRAWN

Philadelphia, Pennsylvania, 19111, United States
Fundacion de Investigacion de Diego (FDI Clinical Research)
COMPLETED

San Juan, 00927, Puerto Rico
Hattiesburg Clinic
RECRUITING

Hattiesburg, Mississippi, 39401, United States
Hightower Clinical Research
COMPLETED

Oklahoma City, Oklahoma, 73102, United States
Hope and Healing Cancer Services
RECRUITING

Hinsdale, Illinois, 60521, United States
Indiana University
RECRUITING

Indianapolis, Indiana, 46202, United States
Ironwood Cancer and Research Centers
RECRUITING

Chandler, Arizona, 85224, United States
James J Peters Veterans Administration Medical Center - NAVREF
WITHDRAWN

The Bronx, New York, 10468, United States
Jefferson Health
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Medical University of South Carolina
WITHDRAWN

Charleston, South Carolina, 29425, United States
Medstar Speciality Hospital
RECRUITING

Northwest, Washington, 20010, United States
Mercy Medical Center
RECRUITING

Baltimore, Maryland, 21202, United States
Midwest Oncology Associates - Kansas City
RECRUITING

Kansas City, Missouri, 64132, United States
Oncology Consultants - Memorial City Location
RECRUITING

Houston, Texas, 77030, United States
Our Lady of the Lake Physician Group - LSU Health Baton Rouge Oncology
RECRUITING

Baton Rouge, Louisiana, 70805, United States
PIH Health Whittier Hospital
RECRUITING

Whittier, California, 90602, United States
Renovatio Clinical
RECRUITING

El Paso, Texas, 79915, United States
Renovatio Clinical
RECRUITING

The Woodlands, Texas, 77380, United States
SSM Health St. Louis DePaul Hospital
RECRUITING

St Louis, Missouri, 63044, United States
Saint Luke's Cancer Institute
WITHDRAWN

Kansas City, Missouri, 64111, United States
Tranquil Research
RECRUITING

Webster, Texas, 77598, United States
UC Irvine Medical Center - Chao Family Comprehensive Cancer
RECRUITING

Orange, Virginia, 22960, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35249, United States
University of Arizona
RECRUITING

Tucson, Arizona, 85719, United States
University of California San Diego
RECRUITING

La Jolla, California, 92093, United States
University of Florida
COMPLETED

Gainesville, Florida, 32610, United States
University of Miami
WITHDRAWN

Miami, Florida, 33146, United States
University of Southern California
RECRUITING

Los Angeles, California, 90033, United States
University of Tennessee -- Memphis
RECRUITING

Memphis, Tennessee, 38163, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37212, United States
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63108, United States
Willis Knighton Cancer Center
RECRUITING

Shreveport, Louisiana, 71103, United States
Zangmeister Cancer Center
RECRUITING

Columbus, Ohio, 43219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.